A number of other research analysts also recently commented on the company. ValuEngine upgraded Agenus from a “hold” rating to a “buy” rating in a research report on Thursday, January 17th. B. Riley assumed coverage on Agenus in a report on Monday, April 22nd. They set a “buy” rating and a $5.00 price target on the stock. Finally, Zacks Investment Research lowered Agenus from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th.
AGEN stock traded down $0.15 during midday trading on Tuesday, hitting $2.63. The company’s stock had a trading volume of 910,676 shares, compared to its average volume of 1,413,717. The company has a market capitalization of $373.24 million, a price-to-earnings ratio of -1.83 and a beta of 1.96. Agenus has a 12 month low of $1.54 and a 12 month high of $3.88.
Institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Agenus by 272.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 23,493 shares during the period. Metropolitan Life Insurance Co. NY bought a new stake in Agenus during the fourth quarter valued at about $80,000. Vanguard Group Inc boosted its position in Agenus by 0.4% during the third quarter. Vanguard Group Inc now owns 4,360,495 shares of the biotechnology company’s stock valued at $9,332,000 after purchasing an additional 18,304 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Agenus by 26.6% during the fourth quarter. Bank of New York Mellon Corp now owns 442,886 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 92,957 shares in the last quarter. Finally, Millennium Management LLC boosted its position in Agenus by 58.8% during the fourth quarter. Millennium Management LLC now owns 1,021,387 shares of the biotechnology company’s stock valued at $2,431,000 after purchasing an additional 378,345 shares in the last quarter. Hedge funds and other institutional investors own 33.08% of the company’s stock.
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Recommended Story: What is a conference call?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.